Company news

Clinuvel Pharmaceuticals Limited news in 2025

Clinuvel Pharmaceuticals Limited's news releases, calls and decks from 2025, newest first.

View company

CLINUVEL expands Singapore RD&I Centre

December 7, 2025

CLINUVEL expands Singapore RD&I Centre to pioneer next-generation peptide therapies

December 6, 2025

CLINUVEL advances new formulations in preclinical program

September 28, 2025

CLINUVEL to advance novel pharmaceutical formulations in preclinical program

September 28, 2025

EMA approves year-round SCENESSE treatment

September 22, 2025

SCENESSE efficacy in vitiligo - new cases presented to EADV

September 18, 2025

Investor Presentation

August 27, 2025

CLINUVEL delivers ninth consecutive revenues growth & profit

August 27, 2025

Appendix 4E and Annual Report to Shareholders 2025

August 27, 2025

CLINUVEL preparing upgrade of ADR program to Level II, Nasdaq uplist

August 22, 2025

CLINUVEL preparing upgrade of ADR program, NASDAQ uplist

August 21, 2025

Study confirms NB-UVB needed to activate repigmentation

June 17, 2025

CLINUVEL management update

June 12, 2025

CLINUVEL recruits 200 patients in Phase III vitiligo trial CUV105

May 7, 2025

CUV recruits 200 patients in Phase III vitiligo trial CUV105

May 6, 2025

CLINUVEL renews share buy-back program

March 26, 2025

Positive preliminary results for PRENUMBRA Instant in stroke

March 25, 2025

Clinuvel Introduces Groundbreaking Vitiligo Program at the World’s Biggest Dermatology Meeting, AAD 2025

March 3, 2025

Half Year Results Announcement

February 27, 2025

Preliminary results from SCENESSE adolescent EPP study

February 9, 2025

Vitiligo - CUV105 Study Update

January 19, 2025

Decks in 2025